Positivity for GPC3, HepPar-1, and Arg-1 in non-hepatocytic malignancies has been well documented throughout the literature.28–31 Our results are similar to those of previously published studies, where the positive expression of GPC3 was observed in ICC (3.1%, 1/32) and metastatic cancers (lung adenocarcinoma, squamous cell carcinoma, neuroendocrine tumours) (18.0%, 11/61), and the positive expression of HepPar-1 was observed in 6.25% of ICC (2/32) and 0.19% of lung adenocarcinomas (1/52). Here, ARG1 is linked to lung adenocarcinoma.